IKT Inhibikase Therapeutics Inc

Price (delayed)

$1.505

Market cap

$9.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.34

Enterprise value

$7.88M

Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional ...

Highlights
The EPS has grown by 20% YoY and by 6% from the previous quarter
The company's debt has surged by 51% YoY but it fell by 21% QoQ
The revenue has increased by 38% YoY but it has decreased by 25% from the previous quarter
IKT's quick ratio has dropped by 76% year-on-year and by 40% since the previous quarter
The equity has dropped by 73% year-on-year and by 38% since the previous quarter

Key stats

What are the main financial stats of IKT
Market
Shares outstanding
6.48M
Market cap
$9.75M
Enterprise value
$7.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.44
Price to sales (P/S)
48.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.23
Earnings
Revenue
$195,980
EBIT
-$19.63M
EBITDA
-$19.45M
Free cash flow
-$15.99M
Per share
EPS
-$3.34
Free cash flow per share
-$2.52
Book value per share
$1.05
Revenue per share
$0.03
TBVPS
$1.75
Balance sheet
Total assets
$11.07M
Total liabilities
$4.29M
Debt
$490,103
Equity
$6.78M
Working capital
$6.57M
Liquidity
Debt to equity
0.07
Current ratio
2.55
Quick ratio
2.3
Net debt/EBITDA
0.1
Margins
EBITDA margin
-9,922.6%
Gross margin
100%
Net margin
-9,797.3%
Operating margin
-10,285.3%
Efficiency
Return on assets
-116.7%
Return on equity
-147%
Return on invested capital
-301.3%
Return on capital employed
-287.1%
Return on sales
-10,013.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IKT stock price

How has the Inhibikase Therapeutics stock price performed over time
Intraday
1.69%
1 week
1.01%
1 month
7.5%
1 year
-44.87%
YTD
18.5%
QTD
14.89%

Financial performance

How have Inhibikase Therapeutics's revenue and profit performed over time
Revenue
$195,980
Gross profit
$195,980
Operating income
-$20.16M
Net income
-$19.2M
Gross margin
100%
Net margin
-9,797.3%
The revenue has increased by 38% YoY but it has decreased by 25% from the previous quarter
Inhibikase Therapeutics's gross profit has increased by 38% YoY but it has decreased by 25% from the previous quarter
The company's net margin fell by 34% QoQ but it rose by 22% YoY
IKT's operating margin is down by 33% since the previous quarter but it is up by 20% year-on-year

Growth

What is Inhibikase Therapeutics's growth rate over time

Valuation

What is Inhibikase Therapeutics stock price valuation
P/E
N/A
P/B
1.44
P/S
48.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.23
The EPS has grown by 20% YoY and by 6% from the previous quarter
The equity has dropped by 73% year-on-year and by 38% since the previous quarter
The stock's price to book (P/B) is 31% more than its last 4 quarters average of 1.1
The revenue has increased by 38% YoY but it has decreased by 25% from the previous quarter

Efficiency

How efficient is Inhibikase Therapeutics business performance
IKT's return on invested capital has dropped by 125% year-on-year and by 70% since the previous quarter
IKT's return on equity has dropped by 107% year-on-year and by 37% since the previous quarter
The return on assets has dropped by 89% year-on-year and by 27% since the previous quarter
The ROS has contracted by 37% from the previous quarter but it has grown by 21% YoY

Dividends

What is IKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IKT.

Financial health

How did Inhibikase Therapeutics financials performed over time
The total assets is 158% greater than the total liabilities
IKT's quick ratio has dropped by 76% year-on-year and by 40% since the previous quarter
Inhibikase Therapeutics's current ratio has shrunk by 75% YoY and by 38% QoQ
The company's debt is 93% lower than its equity
The equity has dropped by 73% year-on-year and by 38% since the previous quarter
The company's debt has surged by 51% YoY but it fell by 21% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.